Lilly collaboration
SanegeneBio raises over $110M Series B after Lilly RNAi deal
SanegeneBio; Series B financing; $110 million; Eli Lilly; RNA interference; RNAi therapeutics; metabolic diseases; Lilly collaboration; clinical-stage assets; liver-targeted RNAi; extrahepatic RNAi; biotech fundraising 2025
Fauna Unveils ‘Fauna Brain’: An Agentic AI System Accelerating Drug Discovery with Proven Results in Lilly Collaboration
Fauna Brain; agentic AI; drug discovery; comparative genomics; Lilly collaboration; multi-agent system; pharmaceutical research; AI platform